ADC Therapeutics SA reports results for the quarter ended in June - Earnings Summary

ADC Therapeutics SA

06/08/2024 14:51

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss
of 38 cents​​ per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of -58 cents.  The mean expectation of seven analysts for the
quarter was for a loss of 46 cents per share. Wall Street
expected results to range from -58 cents to -39 cents per share.
    * Revenue fell 9.7% to $17.41 million from a year ago;
analysts
expected $18.80 million. 
    * ADC Therapeutics SA's reported EPS for the quarter was a
loss
of 38 cents​.
    * The company reported a quarterly loss of $36.54 million.
    * ADC Therapeutics SA shares had fallen by 9.2% this
quarter and
gained 72.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 8.8%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ADC Therapeutics
SA is $10.00 
This summary was machine generated from LSEG data August 6 at
01:51 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -0.46          -0.38          Beat
 Mar. 31 2024      -0.56          -0.56          Met
 Dec. 31 2023      -0.50          -1.03          Missed
 Sep. 30 2023      -0.63          -0.58          Beat